Latest:
Dr Kelly on Ongoing Trials in Patients With GIST
Ciara Kelly, MBBCh, BAO, discusses ongoing trials to further enhance the treatment of patients with gastrointestinal stromal tumor.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Justin Moser, MD
Justin Moser, MD, is a medical oncologist at HonorHealth and an associate clinical investigator at HonorHealth Research Institute.
Latest:
IMA203 Emerges as a Novel Investigational Agent in Cutaneous Melanoma: With Justin Moser, MD
Justin Moser, MD, discusses the ongoing phase 3 SUPRAME trial investigating IMA203 in previously treated, unresectable or metastatic cutaneous melanoma.
Maria Pia Morelli, MD, PhD
Latest:
Dr Morelli on the Ongoing Investigation of A2B530 in Advanced or Metastatic Solid Tumors
Maria Pia Morelli, MD, PhD, discusses the ongoing investigation of A2B530, a Tmod™ CAR T-cell therapy, in advanced or metastatic solid tumors and highlights forward-facing research with the agent.
Shyam A. Patel, MD, PhD
Shyam A. Patel, MD, PhD, is an associate professor at the University of Massachusetts Chan Medical School; as well as a hematologist and oncologist at the UMass Memorial Medical Center.
Latest:
Dr Patel on the p53 IHC Positivity as Potential Surrogate for Multi-Hit TP53 Mutations in MDS and AML
Shyam A. Patel, MD, PhD, discusses the threshold of p53 IHC positivity best correlating with multi-hit TP53 mutational status in MDS and AML.
Zeynep Eroglu, MD
Zeynep Eroglu, MD, is a medical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine.
Latest:
Dr Eroglu on the Role of Triplet vs Doublet Regimens in Melanoma With Symptomatic Brain Metastases
Zeynep Eroglu, MD, discusses the implications of using triplet vs doublet regimens in patients with melanoma who have symptomatic brain metastases.
Dawn Fallik
Latest:
Cracking the Cancer Code Requires Both Quiet and Chaos
Matthew L. Meyerson, MD, PhD, is constantly curious, both about the world and the people around him and as one of the top cancer researchers on the planet, he has a talent for elevating younger scientists, turning obstacles into discoveries, and sensing future research opportunities.
Grace Dy, MD
Latest:
Tusamitamab Ravtansine Plus Ramucirumab as 2L Therapy or Beyond in Patients With Metastatic NSq NSCLC and High CEACAM5 Expression (CARMEN-LC04)
Grace Dy, MD, presents data from the CARMEN-LC04 study evaluating safety and anti-tumor activity of tusamitamab ravtansine combined with ramucirumab in high CEACAM5-expressing non-squamous cell (NSQ) NSCLC tumors.
Memorial Sloan Kettering Cancer Center
Latest:
Memorial Sloan Kettering Cancer Center Launches MSKCC India to Expand Access to World-Renowned Oncologists, Cancer Care, Research, and Education
Memorial Sloan Kettering Cancer Center, the world’s oldest and largest private cancer center, has launched MSKCC India to provide cancer patients in India with access to the institution’s world-renowned oncologists, research, clinical trials, and education.
Rachel Zeig-Owens, DrPH, MPH
Latest:
New Cancer Study Results Confirm Lasting Effects on 9/11 First Responders
Research investigating the physical and mental health consequences of being at the World Trade Center site during and after the terrorist attacks has been instrumental in obtaining health care coverage for thousands of individuals.